|
gptkb:Vizimpro
|
gptkb:non-small_cell_lung_cancer
|
|
gptkb:VMware_Cloud_Verified
|
Cloud provider meets VMware standards
|
|
gptkb:CHEMBL108
|
myocardial infarction
|
|
gptkb:adalimumab_(Humira)
|
gptkb:juvenile_idiopathic_arthritis
|
|
gptkb:Lentigines
|
gptkb:LEOPARD_syndrome
|
|
gptkb:Azilect
|
monotherapy for early Parkinson's disease
|
|
gptkb:Olumiant
|
severe alopecia areata
|
|
gptkb:CHEMBL43016
|
opioid dependence
|
|
gptkb:2014_Index_of_Economic_Freedom
|
government size
|
|
gptkb:H_over_A_mark
|
maker's mark
|
|
gptkb:USDA_Organic_Seal
|
compliance with USDA organic regulations
|
|
gptkb:Motorcycle_Patches
|
gptkb:Chaplain
|
|
gptkb:Cabometyx
|
gptkb:renal_cell_carcinoma
|
|
gptkb:antifibrinolytics
|
gptkb:hereditary_hemorrhagic_telangiectasia
|
|
gptkb:SAPIEN_3_Ultra_valve
|
Patients at high or intermediate surgical risk
|
|
gptkb:ranibizumab-eqrn
|
diabetic retinopathy
|
|
gptkb:Sugemalimab
|
gptkb:stage_III_non-small_cell_lung_cancer
|
|
gptkb:DB01206
|
fibromyalgia
|
|
gptkb:Amjevita
|
rheumatoid arthritis
|
|
gptkb:Follistim_AQ
|
controlled ovarian stimulation
|